What is Integrated Biosciences?
Integrated Biosciences operates at the intersection of computational biology and advanced chemistry, positioning itself as a leader in next-generation drug discovery. By leveraging a sophisticated Integrated Discovery Platform that incorporates optogenetics and high-throughput computational modeling, the firm addresses complex biological challenges associated with the aging process. Their methodology represents a significant departure from conventional small molecule discovery, offering a more precise and scalable approach to therapeutic development. As the company scales, it remains focused on delivering innovative solutions for sectors that demand high-fidelity research and accelerated drug development timelines.
How much funding has Integrated Biosciences raised?
Integrated Biosciences has raised a total of $68.4M across 1 funding round:
Stock/Share Issuance
$68.4M
Stock/Share Issuance (2026): $68.4M, investors not publicly disclosed
Key Investors in Integrated Biosciences
Integrated Biosciences
Undisclosed investor participating in the funding round.
What's next for Integrated Biosciences?
With this major enterprise-level funding, Integrated Biosciences is well-positioned to transition from its current research-heavy phase into a more robust operational scaling stage. The strategic roadmap likely involves expanding the capabilities of their discovery platform to address a broader range of age-related pathologies. Furthermore, the company is expected to prioritize the optimization of its computational pipelines, potentially seeking partnerships with established pharmaceutical entities to validate its findings in clinical settings. This capital deployment will be critical in maintaining their competitive edge as they navigate the complexities of modern drug discovery and long-term health innovation.
See full Integrated Biosciences company page
